52 research outputs found
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
COST-EFFECTIVENESS ANALYSIS OF APREMILAST FOR THE TREATMENT OF ACTIVE PS ORIATIC ARTHRITIS IN GREECE
COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
Background and Objective: Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that has been spread worldwide over the past three decades and associated with increased morbidity and mortality resulting in considerable socioeconomic implications for national healthcare systems. Effective management of disease is highly needed ensuring patients receive the best possible care within the available budget. The objective of this study was to evaluate the long-term cost-effectiveness of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulfonylurea (SU) or a dipeptidyl-peptidase-4 inhibitor (DPP-4i), when added to metformin, in T2DM patients inadequately controlled on metformin alone in Greece. Methods: The published and validated Cardiff diabetes model, a lifetime micro-simulation model, was adapted to a Greek healthcare setting to determine the incidence of micro- and macro-vascular complications and diabetes-specific and all-cause mortality. Clinical, cost, and utility data were retrieved from literature and assigned to model parameters to calculate total quality-adjusted life-years (QALYs) and total costs as well as incremental cost-effectiveness ratios (ICERs). The analysis was conducted from the perspective of a third-party payer in Greece. Uncertainty surrounding important model parameters was explored with univariate and probabilistic sensitivity analyses (PSA). Results: Over a patient’s lifetime, dapagliflozin was associated with 0.48 and 0.04 incremental QALYs compared with SU and DPP-4i, respectively, at additional costs of €5142 and €756, respectively. The corresponding ICERs were €10,623 and €17,695 per QALY gained versus the treatment with SU and DPP-4i, respectively. Results were robust across various univariate and scenario analyses. At the defined willingness-to-pay threshold of €34,000 per QALY gained, PSA estimated that treatment with dapagliflozin had a 100 % and 79.7 % probability of being cost-effective relative to the SU and DPP-4i treatments. Conclusions: Dapagliflozin in combination with metformin was shown to be a cost-effective treatment alternative for patients with T2DM whose metformin regimen does not provide sufficient glycemic control in a Greek healthcare setting. © 2016, Springer International Publishing Switzerland
COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
PSS32 - COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN GREECE
COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN OR EXENATIDE IN PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON ORAL ANTIDIABETIC DRUGS IN GREECE
- …